A Special China Taping of Bloomberg's Trumponomics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Moore Kingston Smith names new China and APAC desk head
Moore Kingston Smith has appointed Lynn Lin as a partner and the head of its China and Asia-Pacific (APAC) desk. Lynn is a Chartered Management Accountant and an ATT-qualified tax adviser, having more than 15 years of experience in both commercial and technical roles across multiple sectors. Moore Kingston Smith managing partner Matt Meadows said: 'Helping businesses achieve their ambitions is what drives us, whether their goals are to expand internationally, attract UK investment or bridge operations across regions. 'To be successful requires experts like Lynn, whose genuine understanding of business culture in both markets supports ambitious clients to grow their global footprint. Welcome to the team, Lynn.' In her new position, Lynn will focus on supporting businesses in their international expansion efforts, which includes establishing overseas subsidiaries, managing compliance and accounting, obtaining funding, and addressing cross-border tax matters. Lynn's work will involve addressing corporate and personal tax matters for business owners and managers, as well as employee incentives and complex transactions. Lynn has a history of assisting businesses in navigating their international growth strategies, stated the accountancy firm. She held roles in commercial finance before moving into professional services. Additionally, Lynn speaks at universities, business chambers, and international forums, sharing insights on cross-border expansion, tax strategy, and commercialisation. Lynn said: 'With a strong international outlook, entrepreneurial spirit and long-term commitment to client partnerships, joining Moore Kingston Smith was an easy decision. 'With an exceptional global network and collaborative culture, the firm offers an ideal platform to support clients on complex cross-border journeys. I'm excited to lead this regionally specialised desk within this forward-thinking firm.' "Moore Kingston Smith names new China and APAC desk head" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Reeves highlights NI investment on Belfast visit
On a visit to Belfast, Chancellor Rachel Reeves emphasised significant investment in Northern Ireland as part of the government's commitment to balanced economic growth across the UK. . Solve the daily Crossword
Yahoo
23 minutes ago
- Yahoo
Here's Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its 'Meridian Growth Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a significant rebound during the quarter, increasing 23% from intra-period lows to close at record highs. Against this backdrop, the fund returned 4.10% (net) compared to the Russell 2500 Growth Index's 11.31% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Meridian Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company. The one-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was 11.11%, and its shares gained 12.32% of their value over the last 52 weeks. On August 11, 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $62.89 per share, with a market capitalization of $7.356 billion. Meridian Growth Fund stated the following regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter: "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as 'new drugs,' potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages—including fewer injection-site reactions and substantial time and cost savings for clinics—making it an important innovation in drug delivery. We slightly reduced our position in the company during the quarter." An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the first quarter, which was 25 in the previous quarter. In the second quarter of 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenue of $326 million, representing 41% year-over-year increase. While we acknowledge the potential of Halozyme Therapeutics, Inc. (NASDAQ:HALO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) and shared the list of most undervalued biotech stocks to buy. Halozyme Therapeutics, Inc. (NASDAQ:HALO) rose in the previous quarter due to strong earnings and its decision to focus on its core business. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
